| Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis A DeCensi, M Puntoni, P Goodwin, M Cazzaniga, A Gennari, B Bonanni, ... Cancer prevention research 3 (11), 1451-1461, 2010 | 1052 | 2010 |
| Aging and endothelial function in normotensive subjects and patients with essential hypertension S Taddei, A Virdis, P Mattei, L Ghiadoni, A Gennari, CB Fasolo, I Sudano, ... Circulation 91 (7), 1981-1987, 1995 | 966 | 1995 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 898 | 2017 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of oncology 32 (12), 1475-1495, 2021 | 680 | 2021 |
| HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials A Gennari, MP Sormani, P Pronzato, M Puntoni, M Colozza, U Pfeffer, ... JNCI: Journal of the National Cancer Institute 100 (1), 14-20, 2008 | 502 | 2008 |
| Cancer and fertility preservation: international recommendations from an expert meeting M Lambertini, L Del Mastro, MC Pescio, CY Andersen, HA Azim, ... BMC medicine 14, 1-16, 2016 | 484 | 2016 |
| Survival of metastatic breast carcinoma patients over a 20‐year period: A retrospective analysis based on individual patient data from six consecutive studies A Gennari, PF Conte, R Rosso, C Orlandini, P Bruzzi Cancer 104 (8), 1742-1750, 2005 | 384 | 2005 |
| Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial B Bonanni, M Puntoni, M Cazzaniga, G Pruneri, D Serrano, ... Journal of clinical oncology 30 (21), 2593-2600, 2012 | 305 | 2012 |
| Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs R Danesi, S Fogli, A Gennari, P Conte, M Del Tacca Clinical pharmacokinetics 41, 431-444, 2002 | 284 | 2002 |
| Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials A Gennari, M Stockler, M Puntoni, M Sormani, O Nanni, D Amadori, ... Journal of clinical oncology 29 (16), 2144-2149, 2011 | 262 | 2011 |
| Breast cancer survivorship, quality of life, and late toxicities S Nardin, E Mora, FM Varughese, F D'Avanzo, AR Vachanaram, V Rossi, ... Frontiers in oncology 10, 864, 2020 | 185 | 2020 |
| Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer DJ Pinato, A Zambelli, J Aguilar-Company, M Bower, CCT Sng, R Salazar, ... Cancer discovery 10 (10), 1465-1474, 2020 | 171 | 2020 |
| Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients M Bellan, G Patti, E Hayden, D Azzolina, M Pirisi, A Acquaviva, ... Scientific reports 10 (1), 20731, 2020 | 135 | 2020 |
| Bevacizumab and breast cancer: A meta‐analysis of first‐line phase III studies and a critical reappraisal of available evidence JR Rossari, O Metzger-Filho, M Paesmans, KS Saini, A Gennari, ... Journal of oncology 2012 (1), 417673, 2012 | 126 | 2012 |
| Cardiotoxicity of epirubicin/paclitaxel–containing regimens: Role of cardiac risk factors A Gennari, B Salvadori, S Donati, C Bengala, C Orlandini, R Danesi, ... Journal of clinical oncology 17 (11), 3596-3602, 1999 | 124 | 1999 |
| Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients A Gennari, S Donati, B Salvadori, A Giorgetti, PA Salvadori, O Sorace, ... Clinical Breast Cancer 1 (2), 156-161, 2000 | 119 | 2000 |
| Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective … DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ... The Lancet Oncology 22 (12), 1669-1680, 2021 | 115 | 2021 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 115 | 2018 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 110 | 2019 |
| Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. PF Conte, E Baldini, A Gennari, A Michelotti, B Salvadori, C Tibaldi, ... Journal of clinical oncology 15 (7), 2510-2517, 1997 | 107 | 1997 |
